CYP2D6 Gene Detection Kit

A diagnostic kit for detecting CYP2C19 gene polymorphisms in human samples to guide personalized medication therapy.

A diagnostic kit for genotyping of the human CYP2C19 gene.

CE IVD real-time PCR kit for detection of CYP2C9 polymorphisms (*2A, *13, HapB3, c2846A>T) according to CPIC and DPWG guidelines. Enables personalized dosing of warfarin and other CYP2C9-metabolized medications.

A gene genotyping detection kit for human CYP2C19 gene analysis using PCR with fluorescent probe methodology. It supports pharmacogenetic testing for precision medicine applications. Available variants: Human CYP2C19 Gene Genotyping Detection Kit (PCR Fluorescent Probe Method).

A molecular diagnostics reagent kit for human CYP2C19 gene typing using PCR with fluorescent probes. The kit supports pharmacogenetic testing for personalized medicine applications.

Genetic testing kit for analyzing drug metabolism genes and predicting medication response. Supports personalized medicine and optimized drug dosing based on genetic profiles.

In vitro diagnostic kit for detecting metabolic enzyme gene polymorphisms to assess individual drug metabolism capacity and guide personalized medication therapy. Uses molecular analysis to identify genetic variants affecting cytochrome P450 and other metabolic enzymes, enabling clinicians to optimize drug selection and dosing based on patient pharmacogenetic profiles.

In vitro diagnostic kit for detecting CYP2C9 and VKORC1 gene polymorphisms to guide warfarin dosing and reduce adverse drug reactions. Enables pharmacogenomic-based anticoagulation therapy optimization in patients requiring warfarin treatment.

A molecular diagnostic kit for DPYD mutation detection. Used in pharmacogenomics and oncology for identifying dihydropyrimidine dehydrogenase gene mutations.

In vitro diagnostic kit for detecting clopidogrel-resistance gene polymorphisms to guide antiplatelet therapy decisions. Uses molecular analysis to identify genetic variants affecting clopidogrel metabolism in patients at risk of thrombotic events. Enables personalized treatment selection and dosing optimization for improved clinical outcomes.

A genotyping kit for CYP2C19 genetic analysis. It is designed for use with the advanced fragment analysis applications platform.

Single nucleotide polymorphism detection kit for pharmacogenomics and disease predisposition analysis. Provides reliable genotyping across large sample populations.